Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: There were 8 mutations in the RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V and rtM309K that were significantly associated with the progression of HCC in treatment-naive patients.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Abstract: Eight mutations in RT (rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K) are significantly associated with HCC progression.
Method: Overall, eight mutations in the RT region, namely rt PMID: 24788140
2014
PloS one
Result: A799G and T1055A are missense mutations resulting in aa substitutions of I224V and M309K, and A987G is a synonymous mutation.
Result: Because the residues from rt304 to rt311 have been reported to be critical for RT activity, we analyzed the relationship between the rtM309K mutation and HBV DNA load.
Table: M309K
Discussion: A799G and T1055A are missense mutations that cause rtI224V and rt PMID: 25503289
2014
PloS one
Table: M309K
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
Abstract: RESULTS: Ten novel RT-mutations (rtN53T-rtS78T-rtS85F-rtS135T-rtA181I-rtA200V-rtK212Q-rtL229V/F-rtM309K) correlated with specific NUC-treatments and classical drug-resistance mutations on divergent evolutionary pathways.
HBV mutation literature information.
PMID: 
2021
Molecular and clinical oncology
Browser Board
Co-occurred Entities
Filtrator
ViMRT